IMM-BCP-01 in Mild to Moderate COVID-19

Summary

The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. The secondary objectives of the study are to: * Determine pharmacokinetics (PK) and evaluate viral clearance after single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. * Evaluate the safety and tolerability, determine PK, and evaluate viral clearance of single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Week 12.

Timeline

Start

2022-06-03

Primary completion

2023-01-06

Completion

2023-01-06

Outcome

Outcome not reported

Stopped (Business): “Business decision to discontinue the study based on strategic prioritization.”

Drugs

Indications